European Union Drugs Agency. (2025) Hepatitis and drug use.
External website: https://www.euda.europa.eu/topics/hepatitis_en
Hepatitis C virus (HCV) infection has a high prevalence in people who inject drugs in Europe, although HCV infection is both preventable and curable. Effective interventions that target the prevention of HCV transmission and the treatment of hepatitis C are needed, particularly for so-called ‘hard to reach’ and vulnerable populations.
Item Type
Webpage
Publication Type
International, Guideline, Web Resource
Drug Type
Substances (not alcohol/tobacco), Opioid
Intervention Type
Harm reduction
Source
Date
2025
Publisher
EUDA
Corporate Creators
European Union Drugs Agency
Place of Publication
Lisbon
EndNote
Accession Number
HRB (Electronic Only)
Subjects
B Substances > Substances in general
B Substances > Opioids (opiates)
G Health and disease > Disease by cause (Aetiology) > Communicable / infectious disease > Hepatitis A (HAV) / D (HDV) / E (HEV)
G Health and disease > Disease by cause (Aetiology) > Communicable / infectious disease > Hepatitis B (HBV)
G Health and disease > Disease by cause (Aetiology) > Communicable / infectious disease > Hepatitis C (HCV)
J Health care, prevention, harm reduction and treatment > Harm reduction > Substance use harm reduction
T Demographic characteristics > Person who injects drugs (Intravenous / injecting)
VA Geographic area > Europe
B Substances > Opioids (opiates)
G Health and disease > Disease by cause (Aetiology) > Communicable / infectious disease > Hepatitis A (HAV) / D (HDV) / E (HEV)
G Health and disease > Disease by cause (Aetiology) > Communicable / infectious disease > Hepatitis B (HBV)
G Health and disease > Disease by cause (Aetiology) > Communicable / infectious disease > Hepatitis C (HCV)
J Health care, prevention, harm reduction and treatment > Harm reduction > Substance use harm reduction
T Demographic characteristics > Person who injects drugs (Intravenous / injecting)
VA Geographic area > Europe
Repository Staff Only: item control page